Latest Michael Wang Stories
Follow-up data from the Phase 2 PCYC-1104 trial presented at the American Society of Hematology Annual Meeting show sustained efficacy and safety over time SAN FRANCISCO and RARITAN, N.J.,
- Note: This press release corresponds to abstracts 4453 and 4471 SAN FRANCISCO, Dec.
- Note: This press release corresponds to abstracts 627 and 1998. SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced by Pharmacyclics, Inc.
In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).
CHONGQING, China, April 14 /PRNewswire/ -- China Redstone Group, Inc. (OTC Bulletin Board: CGPI) ("China Redstone" or the "Company"), the largest private provider of cemetery products and services in Chongqing, China, announced today that it has appointed Mr. S.
Carfilzomib induces a response in 45 percent of patients and reduces neuropathy.
- totally perplexed and mixed up.